Engflag

Prostaglandin E1

Quick links to important sections

Prostaglandin E1

Prostaglandin E1_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostaglandin E1

Property Description
Active ingredient Alprostadil (Prostaglandin E1)
Pharmacological class Prostaglandin Analog, Vasodilator
Origin Synthetic Analog of an Endogenous Eicosanoid
Forms Injectable Solution, Urethral Suppository, Topical Cream
General Purpose To significantly increase local blood perfusion

Prostaglandin E1: Definition and Classification as a Prostanoid Analog

Prostaglandin E1 (PGE1), formally identified by the active non-proprietary ingredient Alprostadil, is a potent vasodilator classified within the Prostaglandin Analog pharmacological group. The pharmaceutical product is a meticulously engineered synthetic analog that chemically mimics the structure and activity of the endogenous eicosanoid naturally produced by the human body. The classification of Alprostadil as a prostanoid is clinically recognized for its unique mechanism of engaging specific cellular receptors, a feature differentiating it from most other systemic vasodilating agents. As an INN, Alprostadil is strictly a prescription drug due to its targeted action and specialized administration methods.

High-Level Action and General Circulatory Purpose

The core physiological action of Alprostadil is the direct induction of smooth muscle relaxation in blood vessel walls, rapidly causing vasodilation and significantly increasing blood flow. This substance also functions as an effective platelet aggregation inhibitor, interfering with the tendency of platelets to clump together. This dual capability makes it particularly valuable in scenarios requiring not only vessel widening but also reduced blood viscosity. A typical neutral use scenario for Alprostadil is when targeted, localized blood flow enhancement is medically necessary.

Composition, Forms, and Delivery Type

Alprostadil is supplied as a single-ingredient product across specialized dosage forms tailored for efficient delivery. These forms, which include the injectable solution (often a powder requiring reconstitution) and the urethral suppository, are designed to maximize the compound's localized effect while minimizing systemic exposure. The different delivery types, such as the use of a lipid-based cream for topical administration versus a sterile solution for injection, represent a primary differentiating factor in its pharmacological application. The composition utilizes the active ingredient Alprostadil combined with appropriate base/vehicle components, chosen specifically for each unique route, such as sterile water for injectable preparations.

Regulatory References

  1. NIH, StatPearls
  2. MedlinePlus

What side effects are possible with Prostaglandin E1?

Official Safety Profile of Prostaglandin E1 (Alprostadil)

The official safety information for Prostaglandin E1 is structured by regulatory bodies to detail adverse reactions based on the frequency of occurrence and the specific route of administration.

Frequency-Classified Adverse Reactions

The following frequency classifications are documented in official regulatory labeling:

  • Very Common (ge 10%): Penile pain (with local adult administration), Apnea (temporary cessation of breathing), Fever (Pyrexia), and Flushing (with intravenous neonatal administration).
  • Common (1% to <10%): Prolonged erection (lasting 4–6 hours), Testicular pain, Hypotension, Dizziness, and Penile fibrosis, which involves structural changes to the penis.
  • Uncommon/Rare (le 1%): Priapism (a prolonged erection lasting ge 6 hours), Seizures, and Cardiac arrest.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions highlighted in regulatory documents include Priapism, which requires immediate attention, and Apnea, which is a significant risk primarily for neonates receiving the intravenous formulation. Long-term use of local formulations is associated with a risk of Penile Fibrosis, which necessitates discontinuation.

Safety constraints prohibit the use of Prostaglandin E1 in men with underlying conditions that increase the risk of prolonged erection, such as sickle cell anemia, or in patients with an anatomical deformation of the penis. The label also contains population-specific safety notes for neonates, advising close monitoring for Apnea, which is most likely to occur within the first hour of infusion.

Overdose and Emergency Response

Overdose Scope and Manifestations

Official regulatory information for Prostaglandin E1 (Alprostadil) specifies different overdose presentations based on the route of administration.

Administration Route Documented Overdose Manifestations Critical Management Action
Intracavernosal (Adults) The primary symptom is a prolonged erection or priapism (an erection lasting longer than six hours). Seek medical help immediately for any erection lasting 4 hours or more to prevent tissue damage.
Intravenous (Neonates) Systemic effects may include apnea (cessation of breathing), bradycardia (slow heart rate), hypotension (low blood pressure), and flushing. For apnea or bradycardia, the infusion must be discontinued and appropriate medical support provided.

When to Seek Immediate Medical Help

Patients using Prostaglandin E1 for erectile dysfunction must be instructed to immediately report to a physician or seek immediate medical assistance for any erection that persists for four hours or longer. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result, highlighting the need for time-critical intervention.

Population-Specific Overdose Considerations

In neonates receiving intravenous infusion, the official labeling notes that apnea is a serious event and is more common in low-birth-weight infants. Management of systemic symptoms like pyrexia or hypotension requires reducing the drug's infusion rate until the symptoms subside.

Therapeutic Uses of Prostaglandin E1

Quick Facts

  • Pediatric Cardiology: Used to help maintain the patency of the ductus arteriosus in newborns with certain congenital heart defects prior to corrective surgery.
  • Urology: Prescribed to address erectile dysfunction in adult males.
  • Vascular: May be utilized to help manage ischemic changes associated with Raynaud phenomenon.

Prostaglandin E1 (alprostadil) is a prescription medication with distinct therapeutic applications. In the field of pediatric cardiology, it is used as a critical measure to temporarily maintain the patency of the ductus arteriosus in neonates who present with specific congenital heart defects that rely on this vessel remaining open until surgical intervention can be performed. This action may help ensure adequate blood flow to the lungs or the body, depending on the nature of the cardiac malformation.

In adult urology, the medication may be considered for the management of erectile dysfunction, particularly when initial oral treatments have not been appropriate or effective. Additionally, Prostaglandin E1 may offer a therapeutic option to address issues related to ischemic changes, such as those experienced by individuals with Raynaud phenomenon. It is a prescription treatment that requires consultation with a healthcare professional for comprehensive information and guidance.

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Neonates with specific congenital heart defects (CHD) requiring maintenance of the patent ductus arteriosus (PDA). Adult Males for the treatment of erectile dysfunction (ED).
Populations for whom use is contraindicated Men with conditions predisposing them to priapism (e.g., sickle cell disease, leukemia). Men with anatomical deformation of the penis, including Peyronie's disease or cavernosal fibrosis. Neonates with established Respiratory Distress Syndrome (RDS).

Age-Related and Condition-Specific Eligibility

Neonates are the only pediatric group approved for use, though those weighing less than 2 kg require close monitoring for apnea. The medication is not indicated for use in the general pediatric population (non-neonates) or in women. Caution is required for use in adult males with kidney or liver impairment, as elimination of the drug may be affected.

Official Eligibility Statements

  • Approved for use in neonates with ductal-dependent congenital heart defects.
  • Contraindicated in men with pre-existing conditions that increase the risk of prolonged erection or those with penile implants.
  • Not indicated for use in female patients; men must use barrier contraception with a pregnant partner as effects on the fetus are not known.

Connection to the overall eligibility profile

Regulatory documents establish the use of Prostaglandin E1 as highly population-specific: it is permitted only for a narrow, life-critical indication in neonates and for a specific local treatment in adult males. Use is absolutely prohibited (contraindicated) for any user with a high risk of priapism or certain penile fibrotic conditions, while use in all other populations, including women and non-neonate children, is officially classified as not indicated by regulators.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Prostaglandin E1 (alprostadil) focuses on pharmacodynamic interactions and specific administration constraints.

Interaction Category Regulatory Statement Summary
Pharmacodynamic Interactions Concomitant use with anticoagulants (e.g., heparin, warfarin) may increase the risk of bleeding at the injection site due to additive effects on hemostasis.
Use with other vasoactive agents can pose a risk of additive effects on blood pressure and may increase the chance of prolonged penile erection (priapism).
Combination Restriction Co-administration with other vasoactive agents injected intracavernosally is generally not recommended as systematic safety and efficacy studies for such combinations are lacking.
Pharmacokinetic Data The potential for drug-drug interactions mediated by CYP enzymes or drug transporters has not been formally studied for the administered drug.

Population-Specific and Clearance Notes

For intravascular use, alprostadil clearance may be reduced in patients with pulmonary disease, which may lead to modified systemic exposure. Official regulatory documents note that the pharmacokinetics have not been formally studied in patients with significant hepatic or renal impairment.

No explicit dose timing or separation requirements for specific interacting agents are formally documented in the regulatory label.

Mechanism of Action

Receptor Agonism and cAMP-Driven Smooth Muscle Relaxation

The mechanism involves Prostaglandin E1 (Alprostadil) acting as an agonist on specific EP2 receptors found on the membranes of vascular smooth muscle cells. This binding rapidly activates the enzyme Adenylate Cyclase, leading to a surge in the intracellular messenger cAMP. This cAMP cascade effectively lowers the free calcium concentration within the cells, which is the critical step for initiating smooth muscle relaxation and resulting in vasodilation (vessel widening).

Modulation of Local Perfusion and Platelet Activity

The functional consequence of this smooth muscle relaxation is a reduction in local vascular resistance, which directly translates into an increase in blood perfusion to the targeted tissues. Furthermore, the elevated cAMP levels interfere with the signaling required for platelet aggregation, thereby inhibiting the aggregation process. This dual-action mechanism of reducing resistance and inhibiting platelet activity contributes to increased local blood flow within the vascular bed.

️ Mechanistic Synergy and Functional Constraints

The cAMP-mediated mechanism is prone to synergistic enhancement when co-administered with other agents that modulate complementary pathways, such as the cGMP pathway, leading to a mechanistically enhanced effect. However, the final physiological outcome remains constrained by external factors, such as local anatomical limitations like pre-existing venous drainage issues, which can override the physiological effects produced by the drug's molecular action.

Dosage and Administration Information

Prostaglandin E1 (Alprostadil) is used via distinct administration protocols, which are determined by the medical application and formulation. Usage must adhere to established routes and controlled frequency patterns.

Administration Route Indication Context Dosing Pattern
Continuous Intravenous (IV) Infusion Pediatric Cardiology Weight-based (0.05 to 0.1 mu g/kg/minute initial)
Intracavernosal Injection Adult Urology Titrated from 1.25 to 2.5 mug; maximum dose not to exceed 60 mug
Transurethral/Topical Adult Urology Dosing for transurethral forms is titrated up to 1000 mug

For injectable formulations, including the powder for intracavernosal use, reconstitution with a specified diluent is required before administration. The solution intended for intravenous use must also be diluted before being administered via continuous infusion.

For adult applications involving injection, use is strictly limited to no more than three times per week, with a mandatory minimum interval of 24 hours between doses. The initial dose and any subsequent adjustments must be established in the healthcare provider's office under medical supervision. The dose is considered optimal when the therapeutic effect does not exceed a duration of one hour, which establishes the goal for appropriate self-administration. The pediatric use for Patent Ductus Arteriosus (PDA) is administered as a continuous infusion calculated by body weight and is maintained at the lowest effective dosage. These procedural steps ensure the compound is handled and administered according to established clinical protocols.

Recent Clinical Evidence

Research Evidence / Overview of studies for Prostaglandin E1

Evidence for Use in Neonatal Heart Defects

The primary research exploring Alprostadil was studied for use in newborns with certain heart conditions relies on observational studies and retrospective clinical data. Studies explored physiological outcomes in neonates, such as the degree of vessel patency and changes in systemic oxygenation, prior to definitive treatment. The research noted that observation periods for patency were typically short, aligning with the goal of stabilization before surgery.

Evidence for Use in Erectile Dysfunction

The research for Alprostadil's use in adult males includes multicenter randomized controlled trials (RCTs). These trials were evaluated in adult males who presented with varying causes of the condition. Studies focused on patient-reported outcomes using functional assessment scores and objective measures of rigidity. Research was also studied for use in acute diagnostic testing to examine vascular changes using tools like Doppler ultrasound.

Studies in Specialized and Subgroup Populations

Research has explored the evaluation of the compound in various specialized populations, including infants with diverse heart defects and adult males with comorbidities like diabetes. While data show patterns related to how the compound was evaluated in these groups, sample sizes were modest in some analyses, meaning results apply only to the populations studied.

Long-Term Follow-up and Durability of Research

For both indications, follow-up durations were limited. For the neonatal indication, comparative evidence from RCTs is lacking. For adult uses, high patient discontinuation rates in longer-duration studies limit data on sustained patterns over many years, and comparative evidence is lacking against certain first-line treatments.

Key Limitations and Research Gaps

For the neonatal indication, the research base primarily consists of established, consistent observational data. For the adult therapeutic uses, the high patient discontinuation rate observed limits the data available for long-term outcomes. Finally, the research highlights that subgroup findings are uncertain because the results apply only to the specific populations studied in the primary clinical trials.

Key Studies & References

  1. Alprostadil Injection, USP (DailyMed - Regulatory Monograph for Neonatal Use)
  2. CAVERJECT IMPULSE- alprostadil injection, powder, lyophilized, for solution (DailyMed - Regulatory Monograph for ED Use)
  3. Alprostadil (StatPearls - NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Prostaglandin E1 (FAQ)

Q: How quickly does Prostaglandin E1 start working for ED when administered as an injection or cream?

Official information regarding the intracavernosal injection (for erectile dysfunction) focuses on the duration of its effect rather than the onset. The goal during dose establishment is to achieve a therapeutic effect that does not exceed a duration of one hour. This goal is used by healthcare professionals when establishing a patient’s appropriate dosage.

Q: What is the usual duration of effect for a Prostaglandin E1 injection for erectile dysfunction?

According to official product information, the dose for intracavernosal injection is considered optimal when the resulting therapeutic effect does not exceed a duration of one hour. This goal is utilized during dose establishment to determine the appropriate individual dosage.

Q: Are there any documented interactions between Prostaglandin E1 and blood-thinning medications (anticoagulants)?

Yes, regulatory documents state that taking Prostaglandin E1 concurrently with anticoagulants, such as heparin or warfarin, may increase the risk of bleeding. This is because combining the two may have an additive effect on the risk of local bleeding, particularly at the injection site.

Q: What are the storage requirements for Prostaglandin E1 injections, especially regarding refrigeration?

The injectable powder form of Prostaglandin E1 must be stored under refrigerated conditions, maintained between 2°C and 8°C (36°F and 46°F). The product should also be protected from light and must not be frozen to maintain its quality.

Q: Why is apnea (decreased breathing) a potential side effect of Prostaglandin E1 in very young infants?

Apnea (temporary cessation of breathing) is a very common and significant risk for neonates receiving the intravenous infusion. Regulatory safety information notes this side effect is most likely to occur within the first hour of starting the infusion. Apnea requires close monitoring because it suggests an effect on central control of breathing, which is a significant risk in neonates.

Q: Can the cream formulation of Prostaglandin E1 be used by a male patient's partner, and what are the implications?

Official eligibility statements note that the effects of Prostaglandin E1 on a developing fetus are not known. For this reason, men are advised to use barrier contraception, such as a condom, when their partner is pregnant. The recommendation for barrier contraception is based on the unknown effects of the drug on a developing fetus.

Q: What should a person do if they notice bruising or a small lump at the injection site after using Prostaglandin E1?

Long-term use of the local formulations is associated with a risk of developing penile fibrosis, which involves structural changes or lumps. If such changes are suspected, the official safety profile advises that the drug may need to be discontinued as determined by a healthcare provider. Any changes, such as bruising or a lump, are recommended to be discussed with a healthcare provider.

Q: What is the potential impact of Prostaglandin E1 on patients with chronic conditions like diabetes or high blood pressure?

Caution is required for adult males with existing kidney or liver impairment, as the body's elimination of the drug may be affected. Official information also notes that using this drug with other vasoactive agents (drugs that affect blood vessels) may have additive effects on blood pressure.

Q: Does the frequency of Prostaglandin E1 injection use affect the chance of developing side effects?

Regulatory documents place strict limitations on the frequency of use. The dosage is restricted to no more than three times per week, with a mandatory minimum interval of 24 hours between doses to manage safety risks, including the development of local adverse reactions.

Q: Is Prostaglandin E1 only for use in adults, or is it also used in infants and children?

Prostaglandin E1 use is strictly limited to specific, approved populations. It is approved only for neonates (newborn infants) with specific congenital heart defects and for adult males for the treatment of erectile dysfunction. It is not indicated for the general pediatric population (older children).

Q: What is 'Trimix,' and is Prostaglandin E1 a component of it?

Prostaglandin E1 (Alprostadil) is classified as a vasoactive agent. Official regulatory documents caution that co-administration with other injected vasoactive agents is generally not recommended due to a lack of safety studies. However, Prostaglandin E1 is a commonly known component of compounded, multi-drug injection combinations used for erectile dysfunction.

Q: Why does Prostaglandin E1 sometimes cause fever or flushing in infants receiving it intravenously?

Fever (pyrexia) and flushing (skin redness) are listed as very common side effects when the intravenous formulation is administered to neonates. These are generally considered systemic effects of the medication. As these may be signs of excessive systemic exposure, a healthcare provider may need to adjust the dosage.

Q: What precautions or monitoring are necessary when Prostaglandin E1 is administered via continuous infusion?

When Prostaglandin E1 is administered as a continuous infusion, especially to neonates, close monitoring is required. This monitoring is critical for the risk of apnea (decreased breathing), which is most likely to occur within the first hour of starting the infusion.

Q: What are the concerns about scar tissue (fibrosis) development with long-term use of Prostaglandin E1 injections for ED?

The official safety profile states that long-term use of the local injection formulation is associated with a risk of penile fibrosis, which involves structural changes to the penis. If this adverse reaction is observed, discontinuation of the drug is generally advised by healthcare professionals.

Q: Does Prostaglandin E1 have any known effects on kidney function, such as preventing contrast-induced injury?

Regulatory documents note that the pharmacokinetics (how the body processes the drug) have not been formally studied in patients with significant renal (kidney) impairment. Regulatory caution is noted for use in patients with compromised kidney function, as elimination of the drug may be affected.

Q: Why do some people with erectile dysfunction not respond to Prostaglandin E1 treatment?

The drug works by relaxing smooth muscle to increase blood flow. However, the final physiological outcome can be limited by external factors. Official information notes that local anatomical limitations, such as pre-existing venous drainage issues in the penis, can override the drug's intended action.

Q: Can Prostaglandin E1 use in infants be associated with gastrointestinal issues like gastric outlet obstruction or NEC?

Official regulatory documents list several gastrointestinal issues as potential adverse effects with intravenous administration in infants. These include diarrhea, gastric regurgitation, and gastric outlet obstruction.

Q: Does Prostaglandin E1 affect the central nervous system, and what are the possible signs of this effect?

Prostaglandin E1 can affect the central nervous system (CNS). Rare but serious reactions, classified as uncommon (less than 1%), include seizures. Additionally, the risk of apnea in neonates suggests an effect on central respiratory control.

Q: Why is Prostaglandin E1 metabolized so quickly in the body, requiring continuous infusion in some applications?

Prostaglandin E1 is rapidly cleared from the bloodstream and extensively metabolized in the body, particularly in the lungs. This rapid clearance is why the drug is administered as a continuous infusion in neonates to maintain a sustained therapeutic effect.

Q: How often should a patient using Prostaglandin E1 injections be monitored by a healthcare professional for safety?

Official administration instructions specify that the initial dose and any subsequent adjustments for the injection must be established in the healthcare provider's office. This process is done under medical supervision to ensure the dose is safe and effective.

Q: Are there any concerns about the long-term effects of Prostaglandin E1 on the bones (cortical hyperostosis) in infants?

Official information notes that a specific change in the bones, called cortical hyperostosis, has been reported in infants. This effect is generally associated with receiving the intravenous infusion for prolonged periods, such as when treatment extends beyond one week.

Q: Is there any research on Prostaglandin E1's effectiveness for women with sexual dysfunction?

Prostaglandin E1 is intended for specific populations. Regulatory documents clearly state that the medication is not indicated for use in female patients.

How should Prostaglandin E1 be stored and disposed of?

How to Store and Dispose of Prostaglandin E1

Storage and disposal of Prostaglandin E1 (alprostadil) are strictly governed by regulatory requirements to ensure product integrity and safety.

Official Storage Requirements

  • Temperature: The injectable powder must typically be stored under refrigerated conditions, maintained between 2°C and 8°C (36°F and 46°F). The product must not be frozen.
  • Protection: The medicine must be kept in its original container and protected from light.
  • Stability: Once the injectable solution is reconstituted or diluted, it must be used within a limited timeframe, often 24 hours, if kept refrigerated.
  • Child Safety: All Prostaglandin E1 formulations must be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Prostaglandin E1 and associated waste should be disposed of in accordance with local requirements. The medicine should not be discarded via wastewater or household waste to comply with pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Prostaglandin E1 found in:

A-Z Index: